Rapid lateral flow tests for the detection of SARS-CoV-2 neutralizing antibodies.

Background: Rapid Lateral Flow Test (LFT) has been broadly utilized in detection or diagnosis of numerous disease-related antigens and antibodies. It is the most popular format of point-of-care test (POCT) and quickest and easiest way to detect a targeted molecule. In the combat against COVID-19 pandemic, hundreds of POCTs have been developed and are commercially available now. They are designed to detect either a SARS-CoV-2 viral antigen or IgG and IgM antibodies binding to it. Among the binding antibodies, a special type of functional antibodies that block the interaction between SARS-CoV-2 virus and its human receptor, neutralizing antibodies (NAbs), are of particular interest to public as well as in vaccination management. However as of today, POCTs for the detection of SARS-CoV-2 NAbs remain under late stage of development.Scope and method:In this review, we first summarize the importance of awareness and monitoring of SARS-CoV-2 NAbs in the combat against COVID-19 pandemic. Secondly, we compare the available methods for the detection of SARS-CoV-2 NAbs. Next, we describe challenges in the development of a rapid lateral flow test for the detection of SARS-CoV-2 NAbs. Finally, we outline its product formats and applications in research and in disease management. Conclusion:Vaccine effectiveness is unknown for an individual unless measured. NAb level is the most viable measurement for vaccine effectiveness or immunity. A broadly accessible NAb POCT is urgently needed.

Covalent Attachment of Fibronectin onto Emulsion-Templated Porous Polymer Scaffolds Enhances Human Endometrial Stromal Cell Adhesion, Infiltration, and Function.

A novel strategy for the surface functionalization of emulsion-templated highly porous (polyHIPE) materials as well as its application to in vitro 3D cell culture is presented. A heterobifunctional linker that consists of an amine-reactive N-hydroxysuccinimide ester and a photoactivatable nitrophenyl azide, N-sulfosuccinimidyl-6-(4'-azido-2'-nitrophenylamino)hexanoate (sulfo-SANPAH), is utilized to functionalize polyHIPE surfaces. The ability to conjugate a range of compounds (6-aminofluorescein, heptafluorobutylamine, poly(ethylene glycol) bis-amine, and fibronectin) to the polyHIPE surface is demonstrated using fluorescence imaging, FTIR spectroscopy, and X-ray photoelectron spectroscopy. Compared to other existing surface functionalization methods for polyHIPE materials, this approach is facile, efficient, versatile, and benign. It can also be used to attach biomolecules to polyHIPE surfaces including cell adhesion-promoting extracellular matrix proteins. Cell culture experiments demonstrated that the fibronectin-conjugated polyHIPE scaffolds improve the adhesion and function of primary human endometrial stromal cells. It is believed that this approach can be employed to produce the next generation of polyHIPE scaffolds with tailored surface functionality, enhancing their application in 3D cell culture and tissue engineering whilst broadening the scope of applications to a wider range of cell types.

Improving advance care planning for English-speaking and Spanish-speaking older adults: study protocol for the PREPARE randomised controlled trial.

INTRODUCTION: Advance care planning (ACP) is a process that allows patients to identify their goals for medical care. Traditionally, ACP has focused on completing advance directives; however, we have expanded the ACP paradigm to also prepare patients to communicate their wishes and make informed decisions. To this end, we created an ACP website called PREPARE (http://www.prepareforyourcare.org) to prepare diverse English-speaking and Spanish-speaking older adults for medical decision-making. Here, we describe the study protocol for a randomised controlled efficacy trial of PREPARE in a safety-net setting. The goal is to determine the efficacy of PREPARE to engage diverse English-speaking and Spanish-speaking older adults in a full spectrum of ACP behaviours. METHODS AND ANALYSIS: We include English-speaking and Spanish-speaking adults from an urban public hospital who are ≥55 years old, have ≥2 chronic medical conditions and have seen a primary care physician ≥2 times in the last year. Participants are randomised to the PREPARE intervention (review PREPARE and an easy-to-read advance directive) or the control arm (only the easy-to-read advance directive). The primary outcome is documentation of an advance directive and/or ACP discussion. Secondary outcomes include ACP behaviour change processes measured with validated surveys (eg, self-efficacy, readiness) and a broad range of ACP actions (eg, choosing a surrogate, identifying goals for care, discussing ACP with clinicians and/or surrogates). Using blinded outcome ascertainment, outcomes will be measured at 1 week and at 3, 6 and 12 months, and compared between study arms using mixed-effects logistic regression and mixed-effects linear, Poisson or negative binomial regression. ETHICS AND DISSEMINATION: This study has been approved by the appropriate Institutional Review Boards and is guided by input from patient and clinical advisory boards and a data safety monitoring board. The results of this study will be disseminated to academic and community stakeholders. TRIAL REGISTRATION NUMBERS: NCT01990235; NCT02072941; Pre-results.